These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34123790)

  • 1. Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Huang J; Huang W; Guo Y; Cai M; Zhou J; Lin L; Zhu K
    Front Oncol; 2021; 11():638428. PubMed ID: 34123790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.
    Cao S; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J; Zou Y
    Cancer Imaging; 2022 Jan; 22(1):2. PubMed ID: 34983650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Hepatocellular Carcinoma Treated by Radiofrequency Ablation-Mid- and Long-Term Outcomes.
    Mukund A; Vats P; Jindal A; Patidar Y; Sarin SK
    J Clin Exp Hepatol; 2020; 10(6):563-573. PubMed ID: 33311893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodized Oil Transarterial Chemoembolization and Radiofrequency Ablation for Small Periportal Hepatocellular Carcinoma: Comparison with Nonperiportal Hepatocellular Carcinoma.
    Lee SY; Hyun D; Cho SK; Shin SW; Jung SH; Chi SA
    Cardiovasc Intervent Radiol; 2018 Jan; 41(1):120-129. PubMed ID: 28924943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns.
    Park W; Chung YH; Kim JA; Jin YJ; Lee D; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Kim PN; Sung KB
    Hepatol Res; 2013 Dec; 43(12):1304-12. PubMed ID: 23442052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis.
    Kim GH; Kim JH; Shim JH; Kim SY; Kim PH; Ko HK; Gwon DI; Shin JH; Lee SJ; Chu HH; Won HJ; Shin YM; Kim N
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38329504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
    Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
    Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
    Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
    Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
    Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.
    Lee DH; Lee JM; Kim PN; Jang YJ; Kang TW; Rhim H; Seo JW; Lee YJ
    Eur Radiol; 2019 Sep; 29(9):5052-5062. PubMed ID: 30770968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
    Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
    Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC.
    Chen SL; Xiao H; Xie ZL; Shen JX; Chen ZB; Wang YQ; Li B; Peng ZW; Kuang M; Lai JM; Peng S
    Eur Radiol; 2020 Jun; 30(6):3473-3485. PubMed ID: 32048035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
    Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C
    BMC Gastroenterol; 2021 Apr; 21(1):182. PubMed ID: 33879085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.